affirm semaglutide GLP-1 Injectable Weight Loss Program select trial semaglutide results Full

After the FDA declared GLP-1 shortages resolved in early 2025 and began cracking down on compounding pharmacies, Ro and Hims & Hers shifted to partnering with Eli Lilly and Novo Nordisk's direct-to-consumer cash-pay pharmacies, LillyDirect (launched January 2024) and NovoCare (launched March 2025), that the manufacturers had built to bypass insurance and PBM channels and capture the unprecedented consumer demand around by GLP-1s, for which ~60% of patients are denied coverage by their insurers

The proper dosing schedule balances efficacy with tolerability, optimizing long-term adherence over short-term speed

Generally, very few studies have investigated incretin levels during childhood and adolescence

This matters because menopause-related changes may influence how your body responds to semaglutide and other weight loss strategies

Varewijck AJ, van der Lely AJ, Neggers S, et al